Contact
Please use this form to send email to PR contact of this press release:
Paras Biopharmaceuticals is Highly Recommended for Biologics CDMO – Development, Scale-up & Production
TO:
Mark Jackson
Paras Biopharmaceuticals Finland Oy
58442905993